omniture

FINRA Confirms China BCT's Corporate Name Change

2010-07-27 21:53 989

LIUZHOU CITY, China, July 27 /PRNewswire-Asia/ -- China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that the Financial Industry Regulatory Authority (FINRA) confirmed the Company's new corporate name, China BCT Pharmacy Group, Inc., effective July 22, 2010.

China BCT's former name was China Baicaotang Medicine Limited. There are no other changes to the Company's corporate structure, management team or business operations. China BCT will continue to be quoted on the Over the Counter Bulletin Board under the ticker symbol "CNBI."

"We believe that our new corporate name more clearly reflects our core business which integrates pharmaceutical distribution, pharmacy retailing, and pharmaceutical manufacturing.  It is also simpler for customers and investors to recognize," commented Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT.

About China BCT

China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates a large regional retail network in Guangxi province, consisting of 125 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network. For more information, please visit http://www.china-bct.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

For more information, please contact:

Company Contact:                        
Ms. Shelly Zhang, Chief Financial Officer     
China BCT Pharmacy Group, Inc.    
Email: shelly.zhang@china-bct.com       
Tel:   +86-772-363-8318  
Web:   http://www.china-bct.com

Investor Relations Contact:              
Mr. Crocker Coulson, President
CCG Investor Relations
Email: crocker.coulson@ccgir.com
Tel:   +1-646-213-1915

Ms. Elaine Ketchmere
VP of Financial Writing
Email: elaine.ketchmere@ccgir.com
Tel:   +1-310-954-1345

CCG Investor Relations
Web: http://www.ccgirasia.com

Source: China BCT Pharmacy Group, Inc.
Related Stocks:
OTC:CNBI
collection